AstraZeneca

Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Shell plc, AstraZeneca, Senior, Rice University, Immunotherapy, Growth, MBA, Entrepreneurship, Autoimmunity, Arizona State University, Pharmaceutical industry

SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer.

Key Points: 
  • SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity, today announced the appointment of Britton Russell as Chief Financial Officer.
  • Mr. Russell brings a wealth of experience working with both emerging growth companies and large multinational organizations to support long-term growth objectives.
  • “Britton brings a unique experience of scaling early stage, innovative life science organizations through significant periods of growth and development,” said Andy Scharenberg, M.D., Co-Founder and Chief Executive Officer of Umoja.
  • I am excited to join the team at this important stage of growth.”
    Mr. Russell joins Umoja after previously serving as Chief Financial Officer at Parse Biosciences, a single-cell sequencing company, and Genapsys, a DNA sequencing company.

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Retrieved on: 
Monday, February 26, 2024
SAN, Chronic kidney disease, AstraZeneca, Anemia, ASH, CKD, MDS, Patient, Disease, Pharmaceutical industry

SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc. Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period. FibroGen’s collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease (CKD) anemia category. In the event FibroGen subsequently monetizes or commercializes roxadustat in the territories formerly licensed under the U.S./RoW collaboration agreement, FibroGen will have certain financial obligations to AstraZeneca.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc. Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period.
  • FibroGen’s collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease (CKD) anemia category.
  • In the event FibroGen subsequently monetizes or commercializes roxadustat in the territories formerly licensed under the U.S./RoW collaboration agreement, FibroGen will have certain financial obligations to AstraZeneca.
  • “We continue to believe that roxadustat represents an important potential therapy for patients in the U.S. and other territories where it has not yet been approved,” said Thane Wettig, FibroGen Chief Executive Officer.

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
SAN, AstraZeneca, Anemia, Syndrome, Investment, Interest, Pancreatic cancer, Growth, Sale, Pamrevlumab, Risk, CKD, LAPC, Society, CIA, Webcast, Patient, IND, Pharmaceutical industry

Fourth quarter FibroGen’s net product revenue under U.S. GAAP from the sale of roxadustat in China was $23.5 million compared to $23.4 million in the fourth quarter of 2022.

Key Points: 
  • Fourth quarter FibroGen’s net product revenue under U.S. GAAP from the sale of roxadustat in China was $23.5 million compared to $23.4 million in the fourth quarter of 2022.
  • Fourth quarter total roxadustat net sales in China¹ by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca (JDE) was $66.5 million, compared to $53.1 million in the fourth quarter of 2022, an increase of 25%.
  • Total revenue for the fourth quarter of 2023 was $27.1 million, as compared to $34.4 million for the fourth quarter of 2022.
  • At December 31, 2023, FibroGen had $248.1 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.

Gracell Biotechnologies Acquisition Completed

Retrieved on: 
Thursday, February 22, 2024
Acquisition, SAN, Cancer, ADS, AstraZeneca, Time in New York, Cayman Islands, Plan, Autoimmune disease, Agreement, Milestone, Bank, Form 6-K, Form, CICA, American depositary receipt, Companies Act, Security (finance), CVR, Sub

The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).

Key Points: 
  • The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”).
  • As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
  • Such letters of transmittal must be completed before such holders can receive the applicable merger consideration.
  • Certificated ADS holders should wait to receive the letters of transmittal before surrendering their ADSs.

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

Retrieved on: 
Thursday, February 22, 2024
Carbon, Occupational safety and health, Sustainability, AstraZeneca, Innovation, Health, Quality, Facility management, Foodservice, University, Business administration, Good, Workplace, Partnership, Pharmaceutical industry

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

Key Points: 
  • Sodexo and AstraZeneca extend their global partnership for a further 5 years.
  • Sodexo and AstraZeneca have built a trusting relationship over the years, with significant advances implemented to improve the daily lives of consumers.
  • The collaboration between Sodexo and AstraZeneca began in 2008 in the UK with a first Food and Facilities Management contract.
  • Johan Stellingwerf, Sodexo Chief Operating Officer for Global Strategic Accounts said: “We are very pleased to have extended our long-lasting partnership with AstraZeneca.

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, February 21, 2024
Cancer, AstraZeneca, EVP, Drug development, Bristol Myers Squibb, RAS, University, RAF, Therapy, Patient, Oncology, Novartis, Paris Diderot University, Physician, Nursing

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.

Key Points: 
  • Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
    Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595
    BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
  • Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company’s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions.
  • Dr. Germa added, “I am thrilled to be joining Ikena at a time when it is primed for clinical inflection across the pipeline.
  • Dr. Santillana’s leadership was integral to bringing our programs into the clinic, and we wish him well in his future endeavors.”

Renewable Thermal Collaborative Releases Case Study on the U.S. Renewable Natural Gas (RNG) Agreement between AstraZeneca and Vanguard Renewables

Retrieved on: 
Monday, March 4, 2024
Green Technology, Food, Beverage, Manufacturing, Environment, Retail, Other Science, Sustainability, Supply Chain Management, Science, Other Energy, Utilities, Oil, Gas, Agriculture, Alternative Energy, Natural Resources, Energy, Other Manufacturing, Supermarket, Carbon, AstraZeneca, Multimedia, Research, Climate, Partnership, Natural gas, British thermal unit, Retirement, Biomass, ESG, Greenhouse gas, PPA, Hope, Learning, ISCC, Renewable resource, RFP, RFI, Heat, Vanguard, Prandtl number, Greenhouse, Digestion, Organization, Patient, Electricity, RTC, Farm, Working Group, Internal, Manure, Methane, GHG, RNG, Renewable energy

The Renewable Thermal Collaborative recently released a case study on the first-of-its-kind partnership between AstraZeneca and Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of AstraZeneca's sites in the United States by 2026.

Key Points: 
  • The Renewable Thermal Collaborative recently released a case study on the first-of-its-kind partnership between AstraZeneca and Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of AstraZeneca's sites in the United States by 2026.
  • Procuring RNG from Vanguard Renewables supports AstraZeneca’s transition to 100% renewable energy, a key element of the company’s flagship Ambition Zero Carbon strategy.
  • Buyers interested in learning more about renewable thermal should:
    Read more case studies from the RTC to learn how energy users and solutions providers are deploying renewable thermal fuels and technologies.
  • The Renewable Thermal Collaborative (RTC) is the global coalition for companies, institutions, and governments committed to scaling up renewable heating and cooling at their facilities.

New Study Addressing Global Concern for Breast Cancer Treatment Now Available in Clifton, N.J.

Retrieved on: 
Monday, March 4, 2024
Research, Pharmaceutical, Oncology, Consumer, Hospitals, Genetics, Clinical Trials, Science, Women, Seniors, FDA, Practice Management, Health, Quality of life, AstraZeneca, MBC, Mutation, ESR1, Patient, Birth control

A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

Key Points: 
  • A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.
  • The SERENA-6 trial, sponsored by AstraZeneca, is a global study that aims to address a critical issue faced by many patients: their treatments become less effective over time.
  • In advanced breast cancer, patients receive a treatment that combines an estrogen-reducing drug with a drug that slows cancer cell growth.
  • This study will evaluate if an experimental trial drug, combined with a cancer-slowing drug, might work better than conventional estrogen-reducing drugs for patients with ESR1 mutations.

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Retrieved on: 
Monday, March 4, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NSCLC, Breast cancer, AstraZeneca, EMA, Doctor of Philosophy, MAA, MD, News, Cancer, Lung, Daiichi Sankyo, ADC, IHC, HER2, HR, DXD, European Medicines Agency, Patient, Maas, Medicine, Lung cancer, Congress, Breast

The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer.

Key Points: 
  • The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer.
  • One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment.
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.
  • “The EMA validation is an important first step toward bringing this TROP2 directed antibody drug conjugate to eligible patients in Europe with nonsquamous lung cancer and HR positive, HER2 negative breast cancer,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.

Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors

Retrieved on: 
Thursday, February 29, 2024
Fashion, Other Retail, Luxury, Retail, Specialty, CFO, Acquisition, Kate Spade, BMY, AstraZeneca, CVS Health, Final good, Senior, Restaurant, Boeing, Multimedia, Pennsylvania State University, Drexel University, SYY, Record, Marketing, Health, Growth, Financial system, University, Business development, Bristol Myers Squibb, BMS, Pharmacy, Executive, Patient, CVS Pharmacy, CVS, Supply chain management, Medical device, Meal, Mid-Atlantic (United States), Management

The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors.

Key Points: 
  • The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors.
  • Kevin and David bring significant strategic and financial expertise, with successful track records of delivering innovation and disciplined global growth, including deep M&A experience.
  • Upon his appointment, Kevin Hourican said, "I am excited to be joining the Board of Directors of Tapestry, an innovative, purpose-driven company with a consumer-led approach to building enduring brands.
  • Upon his appointment, David Elkins stated, “I’m honored to join Tapestry’s Board of Directors at this important chapter in the company’s history.